Asahi Kasei consolidates global pharma units under Asahi Kasei Therapeutics brand

• Asahi Kasei will consolidate its global pharma operations under the Asahi Kasei Therapeutics brand, creating a unified management structure.
• The reorganization folds Japan-based Asahi Kasei Therapeutics, US-based Veloxis, Sweden’s Calliditas, and Germany’s newly acquired AiCuris into one platform.
• Move supports a target of JPY 300 billion in pharmaceutical net sales by FY2030, with capital allocation set at a global level.
• Plan includes about JPY 40 billion for in-licensing over three years, alongside continued investment in existing products and pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Asahi Kasei Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202609290830BIZWIRE_USPR_____20260929_BW608783) on September 29, 2026, and is solely responsible for the information contained therein.